These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 36056951)

  • 1. The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study.
    Li C; Wu J; Jiang L; Zhang L; Huang J; Tian Y; Zhao Y; Liu X; Xia L; E H; Gao P; Hou L; Yang M; Ma M; Su C; Zhang H; Chen H; She Y; Xie D; Luo Q; Chen C
    Cancer Immunol Immunother; 2023 Mar; 72(3):783-794. PubMed ID: 36056951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy.
    Huai Q; Luo C; Song P; Bie F; Bai G; Li Y; Liu Y; Chen X; Zhou B; Sun X; Guo W; Gao S
    Cancer Sci; 2023 Dec; 114(12):4484-4498. PubMed ID: 37731264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study.
    Zhai W; Zhang C; Duan F; Xie J; Dai S; Lin Y; Yan Q; Rao B; Li L; Zhou Y; Zhao Z; Long H; Wang J
    Front Immunol; 2024; 15():1422717. PubMed ID: 39108262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.
    Delikgoz Soykut E; Kemal Y; Karacin C; Karaoglanoglu O; Kurt M; Aytac Arslan S
    J Med Imaging Radiat Oncol; 2022 Feb; 66(1):146-157. PubMed ID: 34632714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
    Xu F; Zhu H; Xiong D; Wang K; Dong Y; Li L; Yuan S
    Thorac Cancer; 2024 Jan; 15(2):172-181. PubMed ID: 38057283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study.
    Liu W; Ren S; Yang L; Xiao Y; Zeng C; Chen C; Wu F; Hu Y
    Int J Surg; 2023 Nov; 109(11):3519-3526. PubMed ID: 37578441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
    Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre study.
    She Y; He B; Wang F; Zhong Y; Wang T; Liu Z; Yang M; Yu B; Deng J; Sun X; Wu C; Hou L; Zhu Y; Yang Y; Hu H; Dong D; Chen C; Tian J
    EBioMedicine; 2022 Dec; 86():104364. PubMed ID: 36395737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy.
    Wang F; Yang H; Chen W; Ruan L; Jiang T; Cheng L; Jiang H; Fang M
    Curr Probl Cancer; 2024 Jun; 50():101098. PubMed ID: 38704949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined inflammatory parameters and tertiary lymphoid structure predict prognosis in patients with resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
    Xu F; Zhu H; Dong Y; Li L; Liu N; Yuan S
    Front Immunol; 2023; 14():1244256. PubMed ID: 38155965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
    Han X; Wang M; Zheng Y; Wang N; Wu Y; Ding C; Jia X; Yang R; Geng M; Chen Z; Zhang S; Zhang K; Li Y; Liu J; Gu J; Liao Y; Fan J; Shi H
    Eur Radiol; 2024 Apr; 34(4):2716-2726. PubMed ID: 37736804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma.
    Zhang X; Gari A; Li M; Chen J; Qu C; Zhang L; Chen J
    J Transl Med; 2022 Feb; 20(1):61. PubMed ID: 35109887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy: a single-center large-cohort study.
    Abravan A; Salem A; Price G; Faivre-Finn C; van Herk M
    Acta Oncol; 2022 Feb; 61(2):163-171. PubMed ID: 34979860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COMPLETE BLOOD COUNT DERIVED INFLAMMATORY BIOMARKERS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES.
    Nanava N; Betaneli M; Giorgobiani G; Chikovani T; Janikashvili N
    Georgian Med News; 2020 May; (302):39-44. PubMed ID: 32672687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CD103
    Li BW; Ren SQ; Chen SL; Lan TJ; Wu F; Li JS
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2023 Dec; 58(12):1257-1264. PubMed ID: 38061868
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancer.
    Han R; Zhang Y; Wang T; Xiao H; Luo Z; Shen C; Li J; Zhao C; Li L; Zhu M; Du H; Tang H; Ma Z; Wang Y; He Y
    Cancer Sci; 2023 Jun; 114(6):2569-2583. PubMed ID: 36880750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive value of systemic immune-inflammatory markers before and after treatment for pathological complete response in patients undergoing neoadjuvant therapy for breast cancer: a retrospective study of 1994 patients.
    Wang H; Huang Z; Xu B; Zhang J; He P; Gao F; Zhang R; Huang X; Shan M
    Clin Transl Oncol; 2024 Jun; 26(6):1467-1479. PubMed ID: 38190034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC.
    Ying HQ; Liao YC; Luo YR; Xiong G; Huang Y; Nie RW; Xiong CF; Cheng XX
    Pharmacol Res; 2021 Aug; 170():105734. PubMed ID: 34157424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.